FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2387296492> ?p ?o ?g. }

• W2387296492 abstract "Abstract Aggressive treatment of AL amyloidosis with high dose intravenous melphalan followed by autologous stem cell transplant (HDM/SCT) is effective in inducing hematologic and clinical remissions associated with prolonged survival. We have performed 593 transplants from July 1994 to December 2012 in the Amyloidosis Center at Boston Medical Center/Boston University School of Medicine. Patients were enrolled in several sequential institutional review board–approved protocols during the 19-year study period. Eligibility criteria for all protocols required biopsy proof of amyloid disease; evidence of a plasma cell dyscrasia and exclusion of other types as appropriate; at least one major affected organ; and adequate measures of cardiac and pulmonary function, and performance status. Functional measures included cardiac ejection fraction 40% or greater, absence of symptomatic pleural effusions, absence of heart failure or arrhythmias resistant to medical management, oxygen saturation of 95% or greater on room air, lung diffusion capacity of 50% or more of predicted, supine systolic blood pressure of 90 mm Hg or greater, and Southwest Oncology Group performance status score of 2 or less unless limited by peripheral neuropathy. Age, renal function, time from diagnosis, prior therapy, and details of the conditioning regimen varied among the trials. Overall, the median age of patients treated with HDM/SCT was 57 years (range, 28-80). Treatment-related mortality (TRM) defined as death occurring within 100 days after SCT occurred in 51 patients, leading to overall TRM of 9% (n=51/593). Additionally, there were 11 deaths during stem cell mobilization and collection phase. No death has occurred since 2005 during stem cell mobilization and collection and TRM has improved to 5% (n=11/235). Total of 324 patients (55%) received full dose melphalan at 200 mg/m2 and 269 (45%) received modified dose melphalan at 100-140 mg/m2 per protocol, based upon age and organ function. Hematologic CR, as defined by international consensus criteria, occurred in 40% (n=202/508) of evaluable patients measured at 6-12 months post SCT; by intention-to-treat the CR rate was 34%. Hematologic CR occurred in 44% (n=129/291) patients who received 200 mg/m2 of HDM compared to 34% (n=73/217) patients who received 100-140 mg/m2 of HDM (chi square p=0.015). Hematologic relapse occurred in 40 patients (20%) with CR at a median of 3.9 years (range, 1.6-12.4). The median overall survival (OS) is 6.7 years with a median follow-up of 4.5 years. The median OS has not been reached for patients achieving a hematologic CR but exceeds 12.4 years, compared to 5.9 years for those not achieving CR (log-rank p<0.001). The median OS for patients following hematologic relapse is 3.5 years. Twenty-five % of patients are alive, up to 19 years after undergoing HDM/SCT. These data highlight the remarkable long-term survival results that can be obtained in patients with AL amyloidosis treated with HDM/SCT. While survival is strongly dependent upon achieving a hematologic CR, the survival of patients who do not achieve a CR and of those who relapse after CR also is notable, suggesting a benefit of treatment. Strategies to improve risk-stratification of patients and reduce TRM, as well as using sequential or combination therapies to increase the CR rate, will likely improve outcomes in the future for patients who just a few years ago were considered to have a rapidly fatal diagnosis. Disclosures: No relevant conflicts of interest to declare." @default.
• W2387296492 created "2016-06-24" @default.
• W2387296492 creator A5010198450 @default.
• W2387296492 creator A5011412033 @default.
• W2387296492 creator A5015549590 @default.
• W2387296492 creator A5026644077 @default.
• W2387296492 creator A5035830218 @default.
• W2387296492 creator A5037990755 @default.
• W2387296492 creator A5064975169 @default.
• W2387296492 creator A5069514993 @default.
• W2387296492 date "2013-11-15" @default.
• W2387296492 modified "2023-09-27" @default.
• W2387296492 title "Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center" @default.
• W2387296492 doi "https://doi.org/10.1182/blood.v122.21.3328.3328" @default.
• W2387296492 hasPublicationYear "2013" @default.
• W2387296492 type Work @default.
• W2387296492 sameAs 2387296492 @default.
• W2387296492 citedByCount "1" @default.
• W2387296492 countsByYear W23872964922021 @default.
• W2387296492 crossrefType "journal-article" @default.
• W2387296492 hasAuthorship W2387296492A5010198450 @default.
• W2387296492 hasAuthorship W2387296492A5011412033 @default.
• W2387296492 hasAuthorship W2387296492A5015549590 @default.
• W2387296492 hasAuthorship W2387296492A5026644077 @default.
• W2387296492 hasAuthorship W2387296492A5035830218 @default.
• W2387296492 hasAuthorship W2387296492A5037990755 @default.
• W2387296492 hasAuthorship W2387296492A5064975169 @default.
• W2387296492 hasAuthorship W2387296492A5069514993 @default.
• W2387296492 hasConcept C126322002 @default.
• W2387296492 hasConcept C141071460 @default.
• W2387296492 hasConcept C159654299 @default.
• W2387296492 hasConcept C203014093 @default.
• W2387296492 hasConcept C2778198053 @default.
• W2387296492 hasConcept C2778684742 @default.
• W2387296492 hasConcept C2779050716 @default.
• W2387296492 hasConcept C2779551797 @default.
• W2387296492 hasConcept C2779951007 @default.
• W2387296492 hasConcept C2780411336 @default.
• W2387296492 hasConcept C2911091166 @default.
• W2387296492 hasConcept C36394416 @default.
• W2387296492 hasConcept C71924100 @default.
• W2387296492 hasConcept C78085059 @default.
• W2387296492 hasConceptScore W2387296492C126322002 @default.
• W2387296492 hasConceptScore W2387296492C141071460 @default.
• W2387296492 hasConceptScore W2387296492C159654299 @default.
• W2387296492 hasConceptScore W2387296492C203014093 @default.
• W2387296492 hasConceptScore W2387296492C2778198053 @default.
• W2387296492 hasConceptScore W2387296492C2778684742 @default.
• W2387296492 hasConceptScore W2387296492C2779050716 @default.
• W2387296492 hasConceptScore W2387296492C2779551797 @default.
• W2387296492 hasConceptScore W2387296492C2779951007 @default.
• W2387296492 hasConceptScore W2387296492C2780411336 @default.
• W2387296492 hasConceptScore W2387296492C2911091166 @default.
• W2387296492 hasConceptScore W2387296492C36394416 @default.
• W2387296492 hasConceptScore W2387296492C71924100 @default.
• W2387296492 hasConceptScore W2387296492C78085059 @default.
• W2387296492 hasLocation W23872964921 @default.
• W2387296492 hasOpenAccess W2387296492 @default.
• W2387296492 hasPrimaryLocation W23872964921 @default.
• W2387296492 hasRelatedWork W2015950109 @default.
• W2387296492 hasRelatedWork W2503758202 @default.
• W2387296492 hasRelatedWork W2526491621 @default.
• W2387296492 hasRelatedWork W2547896281 @default.
• W2387296492 hasRelatedWork W2553319694 @default.
• W2387296492 hasRelatedWork W2554858890 @default.
• W2387296492 hasRelatedWork W2556480163 @default.
• W2387296492 hasRelatedWork W2558837783 @default.
• W2387296492 hasRelatedWork W2567319327 @default.
• W2387296492 hasRelatedWork W2567594949 @default.
• W2387296492 hasRelatedWork W2567720716 @default.
• W2387296492 hasRelatedWork W2576728170 @default.
• W2387296492 hasRelatedWork W2590101487 @default.
• W2387296492 hasRelatedWork W2885807473 @default.
• W2387296492 hasRelatedWork W2923025408 @default.
• W2387296492 hasRelatedWork W2979796411 @default.
• W2387296492 hasRelatedWork W2993862984 @default.
• W2387296492 hasRelatedWork W3011299721 @default.
• W2387296492 hasRelatedWork W3095683256 @default.
• W2387296492 hasRelatedWork W3178193140 @default.
• W2387296492 isParatext "false" @default.
• W2387296492 isRetracted "false" @default.
• W2387296492 magId "2387296492" @default.
• W2387296492 workType "article" @default.